Comparison of interval breast cancer rates for two-versus single-view screening mammography: A population-based study

ObjectiveTo determine whether the implementation of two-view mammography was followed by a reduction in the rates of interval cancers.Material and methodWe analyzed the data concerning women aged 50–69 who attended the breast cancer screening program between January 1, 1994 and December 31, 2006 in Isère, France. We performed Poisson regressions to estimate age-adjusted rate ratios of women being recalled, cancer detection, and interval cancer for two-view compared to single-view mammography.ResultsAfter adjusting for age, two-view mammography was associated with a higher risk of cancer detection (1.37 [95% CI, 1.16–1.62]) and with a decreased risk of 12-month (0.46 [95% CI, 0.23–0.92]) and 24-month (0.64 [95% CI, 0.46–0.88]) interval cancer.ConclusionTwo-view mammography for first and subsequent screens is associated with lower rates of interval breast cancer. This is at the expense of an increased number of women being recalled for further assessment after subsequent screens.     

广州市乳腺癌机会性筛查与团体性筛查结果的比较

目的比较广州市地区机会性筛查与团体性筛查的人群分布,探索影响检查结果阳性的因素。方法机会性筛查的研究对象选取2015年1月~2015年12月来中山大学孙逸仙纪念医院乳腺肿瘤中心就诊的病人,且既往未诊断过乳腺疾病。团体性筛查的研究对象选取同年1月~12月参加我院乳腺肿瘤医学部诊断科开展的广州市女职工(含退休)乳腺癌筛查项目的女性。采用调查问卷的形式,对研究对象采用自填式问卷的方式进行调查。比较两组筛查人群的基本特征,探索影响检查结果阳性的因素。结果研究显示机会性筛查组年龄较团体性筛查组小,初潮年龄较大,哺乳时间较长,初产年龄较年轻,流产次数较多,生育次数也较多。机会性筛查组影像学检查阳性率、活检率均高于团体性筛查组。影响筛查检查阳性结果的独立危险因素是机会性筛查的方式和初潮年龄大于12岁。团体性筛查组确诊的乳腺癌中早期的比例更高。结论团体性筛查组人群分布特征与机会性筛查组不同,检查结果阳性率更高,活检率低于机会性筛查组,但是活检阳性率较高。     

自动乳腺全容积成像结合超声乳腺影像报告和数据系统分类诊断常规超声征象不典型的乳腺癌

目的探讨自动乳腺全容积成像(ABVS)联合乳腺影像报告和数据系统(BI-RADS)分类对常规超声恶性征象不典型(BI-RADS分类3类及4A类)乳腺癌的诊断价值。方法对常规超声BI-RADS分类3类及4A类的832例患者共876个乳腺肿块行ABVS。结合ABVS冠状位图像特点对乳腺肿块重新进行BI-RADS分类。与术后病理结果对照,比较常规超声BI-RADS分类与ABVS结合BI-RADS分类为3类、4A类肿块中恶性率的差异;并以BI-RADS分类≥4B类为恶性肿块诊断标准,评价ABVS结合BI-RADS分类诊断乳腺恶性肿块的效能。结果常规超声BI-RADS分类为3类肿块558个,恶性率4.30%(24/558),4A类肿块318个,恶性率11.01%(35/318)。结合ABVS冠状位图像特点重新分类后,3类肿块455个,恶性率0.66%(3/455);4A类肿块176个,恶性率4.55%(8/176);4B类肿块218个,恶性率14.22%(31/218);4C类肿块27个,恶性率62.96%(17/27)。ABVS结合BI-RADS分类为3类、4A类肿块的恶性率明显低于常规超声分类为3类、4A类肿块(χ~2=11.447、5.951,P=0.001、0.015)。ABVS结合BI-RADS分类对恶性肿块的诊断敏感度、特异度及准确率分别为81.36%(48/59)、75.89%(620/817)及76.26%(668/876)。结论 ABVS结合BI-RADS分类对常规超声恶性征象不典型的乳腺癌具有重要诊断价值。     

Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer

Background: Demand for screening breast magnetic resonance imaging (MRI) for women with a hereditary predisposition to breast cancer has increased since the introduction of a medicare item number. To aid future service planning, we examined the practicalities of establishing and running a breast MRI screening programme for high risk women and to describe the early outcomes of our screening programme. Methods: We undertook a retrospective audit of prospectively collected data. Women <50 years of age with an inherited BRCA1 or BRCA2 gene mutation were invited to undergo annual breast screening with MRI in addition to mammography and clinical breast examination. We assessed process times for booking, performing and reporting MRIs; MRI findings and ease of interpretation; patient recall rate; MRI cancer detection rate; and patient satisfaction via questionnaire. Results: From 2006 to 2009, 82 women completed a round one screening MRI and 45, 21 and one women completed second, third and fourth round annual MRI studies, respectively. Median MRI process times were: booking 20 min; attendance in radiology department 90 min; imaging duration 45 min; reporting by one radiologist 30 min. Of the 82 round one studies, 23 (28%) were reported as ≥Breast Imaging Reporting and Data System three requiring further investigation. Of the round two and three studies completed, 13/45 (28%) and 2/21 (9%) have been recalled, respectively. Seven malignancies were detected. Questionnaires revealed women were satisfied with the service. Conclusions: Significant time, staff and equipment is required to run an effective breast MRI screening programme and this must be considered by future service providers.     

���ٰ���ǰ�������ٴ�ɸ���ֶ�����

早在 18 5 8年Ｖｉｒｃｈｏｗ于其著作《细胞病理学》中提出“癌是细胞的疾病” ,换言之 ,癌细胞由正常细胞演变而来。近年的分子水平研究认为 ,基因突变或调控失常是正常细胞转变为恶性细胞的关键。长期以来临床发现有不少疾病 ,在刺激因素长期作用下 ,通过间变、不典型增生、恶变等癌前病变形式 ,可能发生该器官癌。不言而喻 ,临床上对癌前疾病、癌前病变和癌症易于混淆或漏诊 ,加强这类癌前疾病的筛选 ,实际上对肿瘤的“三早”起着举足轻重的作用。1　乳腺癌癌前疾病的评估严格讲 ,凡是乳腺的先天性结构异常、慢性炎症、增生性病变、良性…     

Overdiagnosis and overtreatment associated with breast cancer mammography screening: A simulation study with calibration to population-based data

ObjectivesThe magnitude of overdiagnosis of breast cancer associated with mammography screening remains controversial because of methodological issues. The objective of this study was to quantify overdiagnosis and overtreatment associated with a population-based screening programme, taking into account lead time and uncertainty concerning baseline incidence of breast cancers.Material and methodsA simulation model was developed to replicate incidence and detection rates of breast cancer observed in the Isère Département, France. The parameters of the model were estimated using an approximate Bayesian computation method.ResultsFor women aged 50–74 years during the 2007–2010 period, overdiagnosis of non-progressive breast cancers accounted for 17.0% (95% credibility interval (CI): 2.5%–35.5%) of all in situ cancers diagnosed, 5.5% (95% CI: 0.8%–9.8%) of all invasive cancers diagnosed, and 20.3% (95% CI: 3.0%–38.9%) of in situ and 13.0% (95% CI: 2.2%–23.3%) of invasive screen detected breast cancers. The estimates of overdiagnosis due to competitive causes of death were 1.0% (95% CI: 0.2%–%1.7) and 1.1% (95% CI: 0.6%–1.7%) for all in situ and invasive cancers diagnosed, respectively, and 1.3% (95% CI: 0.2%–2.0%) and 2.6% (95% CI: 1.4%–4.0%) of all in situ and invasive screen detected breast cancers, respectively.Among 1000 screen-detected cancers in 2010, 155 (95% CI: 27–284), 134 (95% CI: 10–242) and 140 (95% CI: 25–254) women underwent breast conserving surgery, lymph node dissection and radiation therapy for overdiagnosed cancers, respectively.ConclusionOur estimates of overdiagnosis should be balanced against the reduction of breast cancer mortality to assess the value of breast cancer screening programme.     

Estimation of the risk of lung cancer in women participating in a population-based breast cancer screening program

IntroductionLung cancer mortality is increasing in women. In Spain, estimates suggest that lung cancer mortality may soon surpass breast cancer mortality, the main cause of cancer mortality among women. The aim of this study was to estimate the proportion of women at high risk of developing lung cancer in a group of participants in a population-based breast cancer screening program.MethodsCross-sectional study in a sample of women who participated in a population-based breast cancer screening program in 2016 in Hospitalet de Llobregat n = 1,601. High risk of lung cancer was defined according to the inclusion criteria of the National Lung Screening Trial (NLST) and the Dutch-Belgian randomized lung cancer screening trial (NELSON).ResultsAround 20% of smokers according to NLST and 40% of smokers according to NELSON criteria, and around 20% of former smokers according to both criteria, are at high risk of developing lung cancer. A positive and statistically significant trend is observed between the proportion of women at high risk and nicotine dependence measured with the brief Fagerström Test.ConclusionsA high proportion of participants in this breast cancer screening program have a high risk of developing lung cancer and would be eligible to participate in a lung cancer screening program. Population-based breast cancer screening programs may be useful to implement lung cancer primary prevention activities.     

Feasibility of screening for breast cancer.

The feasibility of screening for breast cancer by clinical examination and X-ray mammography has been studied. The results suggest that a breast screening programme is safe from dangers of irradiation and can be conducted by non-medical staff. The response of women at risk suggests that the service is acceptable to the general public. The hospital service could deal with the additional surgical work.     

Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the breast

Background: Dynamic contrast-enhanced magnetic resonance imaging (MRI) of the breast is highly sensitive for the diagnosis of primary breast malignancy. We investigated the clinical application of dedicated dynamic breast MR for routine screening for local recurrence following breast-conserving therapy. Methods: Patients underwent a single dynamic MR of the breast routinely in the period 1 to 2 years following treatment, or earlier if recurrence was suspected. A biopsy was performed if there was suspicion of recurrence on MR. Results: One hundred and five patients with a median age of 58 years (range 50 to 65 years) were recruited for the study. Sixteen biopsies were performed and nine recurrences were confirmed histologically. Patients not undergoing biopsy have been followed up for a median of 341 days (range 168 to 451 days) following the MR. The sensitivity for clinical examination, mammography, examination combined with mammography, and MRI alone for the detection of recurrent cancer were 89%, 67%, 100%, and 100%, respectively, and the specificity was 76%, 85%, 67%, and 93%. Conclusion: Combined clinical examination and mammography are as sensitive as dedicated dynamic MR of the breast for the detection of locoregional recurrence, but breast MRI is associated with a far greater specificity. Therefore, dedicated dynamic breast MRI should be used when there is clinical or mammographic suspicion of recurrence to confirm or refute its presence.Presented at the 50th Annual Cancer Symposium of The Society of Surgical Oncology, Chicago, Illinois, March 20–23, 1997.     

Effect of screening mammography on the surgery of breast cancer in Finland: a population-based analysis during the years 1985-2004

A nationwide mammographic screening of women aged 50 to 59 years commenced in Finland in January 1987. We studied the effect of screening on surgical diagnosis, treatment, and survival of breast cancer in one geographic area in Finland. We reviewed the medical records, survival data from Finnish Cancer Registry, and screening data from the Finnish Mammogrphic Working Group of 1049 women who underwent surgery for breast cancer in our hospital between the years 1985 and 2004. Altogether, 35 parameters including diagnostic procedures, operative data, and staging were recorded. The results of tumors detected by mammographic screening (n=156) and interval cancers (n=148) were compared with the tumors detected outside of screening (n=745). The incidence of breast cancer increased from 35 to 72 cases per 100,000 inhabitants, and the percentage of nonpalpable cancers increased from 12 to 33. Approximately 30 women per 100,000 inhabitants were annually referred from mass screening for surgical biopsies, in 60 per cent of which cancer was detected. Breast lump was still a first sign of cancer in 60 per cent of patients. The mammographic screening detected 20 per cent of new breast cancers. The cancers detected by screening were smaller, found at an earlier stage, and their 10-year-survival was better (90% vs 70%) than those detected by other means (P = 0.003). Overall mortality of interval cancers was worse (27%) than screening cancers (6%, P < 0.0001). Mammographic screening detects up to 20 per cent of new breast cancers in a well-defined population area. The prognosis of screening cancers is better than the cancers found outside of screening.     

An evaluation of mass screening for breast cancer

In Tokushima Prefecture, Japan, 41,922 women (26,669 in actual number) were subjected to mass screening with physical examination from 1970–1977. In 42 including 10 of so-called “interval cancer”, breast cancer was detected. Those with breast cancer detected by mass screening were in the earlier stage of the discase as compared to those diagnosed through regular medical care at our out-patient clinic during the same period. Procedures such as inspection and palpation are readily carried out and early occurrences of breast cancer can be detected.     

Nodal positivity in breast cancer correlated with the number of lesions detected by magnetic resonance imaging versus mammogram

Background

Magnetic resonance imaging (MRI) in breast cancer can detect more than 15% additional lesions than mammography. We investigated lymph node metastases rates in patients with multifocal or multicentric disease detected by MRI compared with patients with a single lesion detected by mammography and magnetic resonance imaging.

Methods

A retrospective analysis of breast cancer patients undergoing MRI and mammography was performed. The objective was to compare lymph node metastases rates in patients with additional lesions detected by MRI versus a single lesion detected by mammography or MRI.

Results

Of 413 patients, 318 were included for the study. The overall nodal metastases rate was 24.8%. MRI detected multiple lesions in 83 (26.1%) patients; 67 (21.1%) patient MRI findings were not detected by mammography. The lymph node metastases rate was 37.3% when ≥2 lesions were detected compared with 20.2% when a single malignant lesion was detected (P = .01). The evaluation of the 67 patients with additional lesions detected by MRI revealed 32 patients with invasive lesions, 29 with benign lesions, and 6 with in situ disease. Comparing patients with single malignant lesions with patients with additional malignant lesions detected by MRI, the lymph node metastases rate increased from 20.2% to 50% (P = .002).

Conclusions

Our study shows a significant increase in the lymph node metastases rate in patients with additional malignant lesions detected by MRI. This finding suggests that MRI-detected malignant lesions are biologically significant and may predict more aggressive disease.     

Association of breast cancer with papillary lesions identified at percutaneous image-guided breast biopsy

BACKGROUND: The management of papillary lesions identified on image-guided breast biopsy remains controversial. In the literature, data regarding papillary lesions are limited because of small sample sizes. The purpose of this study was to identify the prevalence of atypical ductal hyperplasia and malignancy associated with papillary lesions identified on image-guided breast biopsy. METHODS: This study is a retrospective review of 9,310 consecutive image-guided biopsies performed at our institution between January 1996 and November 2003. Patients were included if they underwent an excisional biopsy after a papillary lesion was diagnosed on image-guided biopsy. RESULTS: Papillary lesions were identified in 153 (2%) of the 9,310 image-guided biopsies performed, and 87 of these patients underwent subsequent excisional biopsy at our institution. Breast cancer (in situ or invasive) was identified in 15 patients (17%), and 16 patients (18%) had atypical ductal hyperplasia identified at excisional biopsy. CONCLUSIONS: These data suggest that excisional biopsy should be considered when a papillary lesion is identified at percutaneous image-guided breast biopsy. The final surgical pathology may impact the treatment plan, risk reduction, and/or surveillance for more than a third of patients diagnosed with a papillary lesion on image-guided biopsy.     

Quality of life among a population-based cohort of older patients with breast cancer

BackgroundGrowing numbers of older women receive adjuvant breast cancer therapies, but little is known about the long-term effects of current therapies upon health-related quality of life outside of clinical trials.MethodsA population-based cohort of postmenopausal women with incident breast cancer aged sixty-five and older was identified from Medicare claims from four states and followed over five years. General health-related quality of life (HRQOL) was assessed using the Medical Outcomes Study SF-12 Health Survey, and breast cancer-related HRQOL was assessed using the breast cancer subscale of the functional assessment of cancer therapy (FACT-B BCS). The association of HRQOL with sociodemographic variables, comorbidity, and breast cancer variables (stage, treatments, and treatment sequelae) was examined in longitudinal models.ResultsAmong the 3083 older breast cancer survivors, general HRQOL as measured by SF-12 mental and physical component scores was similar to norms for non-cancer populations, and remained stable throughout follow-up. Breast cancer treatments, including surgery and radiation, adjuvant hormonal therapy, and cytotoxic chemotherapy were not associated with worsened general health scores. A similar pattern was seen for breast cancer-related HRQOL scores, except that chemotherapy was associated with slightly worse scores. Lymphedema occurred in 17% of the cohort, and was strongly associated with all measures of HRQOL. Reductions in general HRQOL with lymphedema development were larger than those with an age increase of 10 years.ConclusionsThere is little association of breast cancer treatment with HRQOL in older breast cancer patients followed for up to five years, but the development of lymphedema is associated with substantial reductions in HRQOL.     

Systematic review of 3D mammography for breast cancer screening

This review investigated the relative performance of digital breast tomosynthesis (DBT) (alone or with full field digital mammography (FFDM) or synthetic digital mammography) compared with FFDM alone for detecting breast cancer lesions in asymptomatic women. A systematic review was carried out according to systematic reviewing principles provided in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. A protocol was developed a priori. The review was registered with PROSPERO (number CRD42014013949). Searches were undertaken in October 2014. Following selection, five studies were eligible. Higher cancer detection rates were observed when comparing DBT + FFDM with FFDM in two European studies: the summary difference per 1000 screens was 2.43 (95% CI: 1.8 to 3.1). Both European studies found lower false positive rates for individual readers. One found a lower recall rate based on conditional recall. The second study was not designed to compare post-arbitration recall rates between FFDM and DBT + FFDM. One European study presented data on interval cancer rates; sensitivity and specificity for DBT + FFDM were both higher compared to FFDM. One large multicentre US study showed a higher cancer detection rate for DBT + FFDM, while two smaller US studies did not find statistically significant differences. Reductions in recall and false positive rates were observed in the US studies in favour of DBT + FFDM. In comparison to FFDM, DBT, as an adjunct to FFDM, has a higher cancer detection rate, increasing the effectiveness of breast cancer screening. Additional benefits of DBT may also include reduced recalls and, consequently, reduced costs and distress caused to women who would have been recalled.     

Assessment of tumor size for multifocal primary breast cancer

Background: Tumor size affects the choice of surgical procedure and patient prognosis. It is standardly assessed as the largest unidimensional measurement and, for multifocal disease, as the largest size of the largest focus. We examine some different methods of assessing tumor size: the standard method; the sum of the largest sizes for all foci; surface area; and volume. Methods: Data for a cohort of 678 primary invasive breast cancer patients accrued from 1971 to 1990 were updated to 1996; there were 571 patients with unifocal disease and 107 patients with multifocal disease. We used step-wise Cox regression to investigate the effects on time to death of the prognostic factors tumor size (estimated in one of the four ways), age, nodal status, ER, PgR, adjuvant radiotherapy, adjuvant hormonal therapy, and adjuvant chemotherapy. We also examined the association between tumor focality and nodal status. Results: For all patients, tumor size was included in the multivariate model, regardless of estimation method. For patients with multifocal disease, tumor size was included in the final model only when it was estimated as the total surface area (P=.03) or volume (P=.01) of the foci. More multifocal patients were N+ (P=.056). Conclusions: For patients with multifocal disease, the significance association with mortality for total surface area or volume may imply a biologic relevance or mode of tumor activity for the foci.